NC
VNDA icon

Nexthera Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Nexthera Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-462,200
Closed -$7.53M – 45
2017
Q2 		$7.53M Sell
462,200
-50,000
-10% -$721K 3.28% 15
2017
Q1 		$7.17M Buy
+512,200
New +$7.3M 3.66% 12

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital's VNDA Position: Q3 2017 in Review

Nexthera Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2017, closing a stake of 462,200 shares — an estimated $7.53M sold.

Nexthera Capital first reported a position in VNDA in Q1 2017 and held it in 2 quarters. The position peaked at $7.53M in Q2 2017. 137 funds tracked by Wall St. Rank hold VNDA as of Q3 2017.

  • Nexthera Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Nexthera Capital sold 462,200 Vanda Pharmaceuticals shares in Q3 2017, an estimated $7.53M.
  • Nexthera Capital first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Nexthera Capital's Vanda Pharmaceuticals position peaked at $7.53M in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2017.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.